欧洲和泰国儿童青少年HIV感染者使用多替拉韦的病毒抑制、病毒学失败及安全性结局
本研究评估0-18岁儿童青少年HIV感染者启动多替拉韦(DTG)后的病毒抑制、病毒学失败(VF)及安全性。1230例中位随访93周,病毒抑制率88%-91%,第96周和144周VF累积发生率分别为4.3%和8.3%。DTG耐受良好,但启动时已接受ART且病毒血症者VF风险显著更高,需密切监测。
要点
- DTG治疗期间病毒抑制(VL<50 copies/mL)率维持在88%-91%。
- 第96周和144周VF累积发生率分别为4.3%和8.3%。
- 启动DTG时已接受ART且病毒血症者VF风险显著增加,需密切监测。
核心结论
- DTG耐受良好,约90%的儿童青少年HIV感染者病毒抑制<50 copies/mL。
- VF总体较低,但在启动DTG时已接受ART且病毒血症的儿童青少年中显著更高,需要密切监测。
研究设计与样本
- 在歐洲和泰國常规诊疗中评估0-18岁启动DTG的儿童青少年HIV感染者的有效性和安全性。
- 共纳入1230例儿童青少年,中位年龄14岁(IQR 11-16),49%为女性,中位DTG治疗时长93周(IQR 49-163)。
主要发现
- 病毒抑制(VL<50 copies/mL)在整个随访期间为88%-91%。
- 第96周和第144周VF累积发生率(95% CI)分别为4.3%(3.1%-6.1%)和8.3%(6.2%-11.1%)。
- VF风险增加与女性、已接受ART且病毒血症、晚期/严重免疫抑制、既往治疗失败及地区相关(P < .05,校正年龄、性别和ART/VL状态)。
- DTG治疗者的VF风险低于基于蛋白酶抑制剂的方案(P < .001)。
- 1146例有临床数据者中26例(2%)发生52例DTG相关不良事件,包括5例严重不良事件;849例有实验室数据者中44例(5%)发生54例≥3级事件(<1/100人年)。
临床怎么用
- DTG在儿童青少年HIV感染者中耐受良好,病毒抑制率高。
- 对启动DTG时已接受ART且病毒血症的儿童青少年需密切监测病毒学失败。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dolutegravir (DTG) is a preferred anchor antiretroviral therapy (ART) for children and adolescents with HIV (CAWH). METHODS: We assessed the effectiveness and safety of DTG in CAWH aged 0-18 years at DTG start in routine care in Europe and Thailand, evaluating viral suppression (viral load [VL] <50 copies/mL), cumulative incidence and associated factors of viral failure (VF; confirmed VL ≥400 copies/mL) and safety outcomes. RESULTS: Of 1230 CAWH on DTG, 49% were female. At DTG start, median (IQR) age was 14 (11-16) years, 10% were ART-naive, 49% ART-experienced/suppressed (VL <200 copies/mL), 13% ART-experienced/viremic (VL ≥200 copies/mL), and 28% ART-experienced/unknown VL. Median duration on DTG was 93 (49-163) weeks. Virall suppression was 88%-91% throughout follow-up. Cumulative incidence (95% CI) of VF at weeks 96 and 144 was 4.3% (3.1%-6.1%) and 8.3% (6.2%-11.1%). Increased risk of VF was associated with female sex, ART-experienced/viremic, advanced/severe immunosuppression, previous treatment failure, and region (P < .05, adjusting for age, sex and ART/VL status). The risk of VF was lower on DTG than CAWH on protease-inhibitor-based regimens (P < .001). Among 1146 with clinical data, 26 (2%) experienced 52 DTG-related adverse events, including 5 serious adverse events. Of 849 with laboratory data, 44 (5%) had 54 grade ≥3 events (<1 per 100 person-years). DTG discontinuation by weeks 96 and 144 was 5.0% (3.8%-6.7%) and 9.5% (7.5%-12.0%). CONCLUSIONS: DTG was well tolerated, with ∼90% virally suppressed <50 copies/mL. VF was low overall but was significantly higher in children/adolescents ART-experienced and viraemic at DTG start, requiring close monitoring.
引用
- Scott K, O'Rourke J, Jackson C, et al. Viral Suppression, Viral Failure, and Safety Outcomes in Children and Adolescents With HIV on Dolutegravir in Europe and Thailand. Clin Infect Dis. 2025. PMID: 40215206. doi:10.1093/cid/ciaf191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。